F. Hoffmann-La Roche Ltd: Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple scleros ...
The Manila Times

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to ...